Navigation Links
Pharmacyclics Reports First Quarter 2013 Results
Date:5/1/2013

hromosome 17p.

The Breakthrough Therapy Designation is intended to expedite the development and review of a potential new drug for serious or life-threatening diseases where "preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development." The designation of a drug as a Breakthrough Therapy was enacted as part of the 2012 Food and Drug Administration Safety and Innovation Act. Pharmacyclics, together with Janssen, is working with the FDA to determine the implications of this Breakthrough Therapy Designation to the ongoing and planned development and the filing requirements for the use of ibrutinib in patients. At this time Pharmacyclics is targeting to submit the MCL filing before the end of the third quarter 2013. Pharmacyclics anticipates to provide guidance prior to year end on the WM and CLL with deletion 17p filing timelines after further discussions with the FDA.

The FDA Breakthrough Therapy Designations for ibrutinib were based on data from clinical and pre-clinical studies. Ibrutinib has the potential to improve the outcome in these serious and life-threatening diseases which have a poor prognosis. The company and its collaboration partner, Janssen, have designed and are currently executing a development program for ibrutinib in each of these indications.

Comprehensive Pre-Clinical Research and Clinical Development To broaden our understanding of ibrutinib, Pharmacyclics has performed research into mechanisms of action both in its own research department, and through collaborations with leading universities and clinical centers. Over the past 3 years, Pharmacyclics' research department has established and maintained 47 collaborations with academic investigators at universities or clinical centers. This broad-reaching collaborative effort has resulted
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
2. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
3. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
4. Pharmacyclics, Inc. Prices Public Offering of Common Stock
5. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
6. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
7. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
8. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
9. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
10. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
11. Hospira Reports First-Quarter 2013 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 22, 2014 Research ... addition of the  "Global Operating Room Equipment ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,An operating ... environment in a healthcare facility used to ... technically advanced equipment, which ensures patient care ...
(Date:8/22/2014)... /CNW/ - On Aug. 20, at its annual meeting ... Association (CMA) voted on and approved a delegate resolution ... cannabis. Bedrocan Cannabis Corp., a leading Canadian licensed producer ... The CMA is quite right to point ... any plant material, including medicinal cannabis. While some patients, ...
(Date:8/22/2014)... , Aug. 22, 2014 Research and ... "Global and Chinese Intravenous Catheter Industry Report 2014" ... and Chinese Intravenous Catheter Industry Report 2014 is a ... the global intravenous catheter industry with a focus on ... overview of the industry including definitions, classifications, applications and ...
Breaking Medicine Technology:Global Operating Room Equipment Market 2014-2018: Key Vendors are Getinge, STERIS, Stykron and TRUMPF Medical Systems 2Bedrocan Canada Statement Regarding Canadian Medical Association Motion on Smoking Marijuana 2Global and Chinese Intravenous Catheter Industry Report 2014 2
... 2, 2012 CVS Caremark Corporation (NYSE: CVS ) ... months ended March 31, 2012. (Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO ... , Net revenues increased 19.9% to a record $30.8 ... , Retail Pharmacy segment same stores sales increased ...
... Ill., May 2, 2012  Celebrity chef Spike Mendelsohn knows all ... – especially for a person with acid reflux disease (ARD). ... Spike has also had to learn how to turn down ... awareness and understanding about the importance of managing heartburn symptoms ...
Cached Medicine Technology:CVS Caremark Reports Record First Quarter Results 2CVS Caremark Reports Record First Quarter Results 3CVS Caremark Reports Record First Quarter Results 4CVS Caremark Reports Record First Quarter Results 5CVS Caremark Reports Record First Quarter Results 6CVS Caremark Reports Record First Quarter Results 7CVS Caremark Reports Record First Quarter Results 8CVS Caremark Reports Record First Quarter Results 9CVS Caremark Reports Record First Quarter Results 10CVS Caremark Reports Record First Quarter Results 11CVS Caremark Reports Record First Quarter Results 12CVS Caremark Reports Record First Quarter Results 13CVS Caremark Reports Record First Quarter Results 14CVS Caremark Reports Record First Quarter Results 15CVS Caremark Reports Record First Quarter Results 16Chef Spike Mendelsohn Dishes on How to Turn Down the Heat on Acid Reflux Disease 2Chef Spike Mendelsohn Dishes on How to Turn Down the Heat on Acid Reflux Disease 3Chef Spike Mendelsohn Dishes on How to Turn Down the Heat on Acid Reflux Disease 4Chef Spike Mendelsohn Dishes on How to Turn Down the Heat on Acid Reflux Disease 5
(Date:8/23/2014)... Dallas, Texas (PRWEB) August 23, 2014 ... deterioration of the function of the myocardium (the ... heart failure; common symptoms are dyspnea (breathlessness) and ... cardiomyopathy are often at risk of dangerous forms ... The most common form of cardiomyopathy is dilated ...
(Date:8/23/2014)... Peripheral intervention surgeries are part of the ... addressing the root cause of peripheral artery disease. Peripheral ... other part of the arteries where the blood clot ... the use of a catheter, (which is a thin ... are inserted through a thin cut in an artery, ...
(Date:8/23/2014)... York, New York (PRWEB) August 23, 2014 ... http://www.consumerinjurylawyers.com/wright-conserve-hip-replacement.html ) filed on behalf of individuals ... the Conserve hip replacement line continue to move ... of Georgia, Bernstein Liebhard LLP reports. According to ... established a bellwether trial program that would allow ...
(Date:8/23/2014)... 2014 Professional kitchen employees, prospective chefs ... in preparing for Food Safety Certification exams thanks to ... Dynamic Path. , Dynamic Path announced the release of ... than 200 review questions for culinary industry students and ... cover requirements of the ServSafe® Food Safety Certification, National ...
(Date:8/23/2014)... August 23, 2014 Teen drug and ... It’s no different in Wilmington, NC. Substance abuse can ... falling victim to drug and alcohol dependency in higher ... looking to overcome substance abuse, but don’t know where ... treatment facility can be a challenge because most treatment ...
Breaking Medicine News(10 mins):Health News:Cardiomyopathy (Heart Muscle Disease) Therapeutics Clinical Trials Market 2014 Analysis in a New Report Available at MarketOptimizer.org 2Health News:Cardiomyopathy (Heart Muscle Disease) Therapeutics Clinical Trials Market 2014 Analysis in a New Report Available at MarketOptimizer.org 3Health News:Cardiomyopathy (Heart Muscle Disease) Therapeutics Clinical Trials Market 2014 Analysis in a New Report Available at MarketOptimizer.org 4Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 2Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 3Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 4Health News:Food Handler Safety Certification Made Easy with Dynamic Path 2Health News:Troubled Teens Wilmington Helpline Guides Adolescents to the Path of Recovery 2
... thermal performance of protective clothing worn by firefighters. A ... the burns received by firefighters when they are not ... burns. Researchers at North Carolina State University have developed ... suits to be evaluated for their ability to prevent ...
... and nutritional benefits; Packaging now more environmentally responsibleNEW YORK, ... to the enhanced water category, PepsiCo (PEP) is re-launching ... water beverage designed to help hydrate and nourish the ... Propel is available in a variety of ...
... In recognition of April as National Autism Awareness Month, LoJack Corporation ... at: http://www.lojack.com/knowledge/Documents/AutismAwarenessMonth.mp3 ) that provided valuable ... The rising incidence of autism in ... challenges of caring for an autistic child , ...
... no problems at 6 months of use , , TUESDAY, ... Cialis (tadalafil) and Viagra (sildenafil) didn,t appear to damage ... six months, according to a drug company study. , ... treat erectile dysfunction by interfering with the action of ...
... marketing exclusivityPITTSBURGH, April 14 Mylan Inc. (Nasdaq: ... its subsidiary Mylan Pharmaceuticals Inc. have been sued by ... an Abbreviated New Drug Application (ANDA) with the U.S. ... mg and 500 mg, the generic version of Xeloda(R) ...
... WILMINGTON, Del., April 14 Patent litigation firm Teuton, ... Therative, Inc. on behalf of inventor Joseph Neev, PhD. ... District Court, District of Delaware, Dr. Neev claims sole ... issued patent that Therative claims protects its ThermaClear Acne ...
Cached Medicine News:Health News:NC State develops new test method to measure stored heat in firefighter suits 2Health News:Propel Unveils New Enhanced Experience 2Health News:Propel Unveils New Enhanced Experience 3Health News:April is National Autism Awareness Month: LoJack Hosts Educational Podcast Featuring Panel of Experts Addressing Autism Issues 2Health News:Impotence Drugs Don't Harm Vision: Study 2Health News:Mylan Confirms First-to-File Patent Challenge Relating to Xeloda(R) Cancer Treatment 2Health News:Inventor Sues Therative, Inc. Over Inventorship of Patent on ThermaClear Device; Separate Invention Theft Case Continues 2
Angled shaft with 0.2 tip, round serrated handle, dull finish, overall length 130 mm...
... simplus multi-action solution is the first and ... only cleans, disinfects and conditions gas permeable ... with cleaning comparable to the leading two-bottle ... system provides comfort upon insertion by enveloping ...
Menicon Z is a rigid gas lens with high oxygen permeability. As one of its specific characteristics, it can provide superior visual correction and show excellent performance against astigmatism....
... using sophisticated lathing techniques, intrinsically permeable polymers ... a center thickness of just 0.08 across ... powered Thinsite lenses maintain a 30% decrease ... unique design eliminates stress points to reduce ...
Medicine Products: